---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-025180"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T12:03:25.088101+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OPKO reports Q2 net loss $10.3M; enters $250M note deal, plans $100M buyback

## Summary
- Q2 total revenues $182.2M (down from $265.4M YoY); operating loss $61.7M vs income $7.0M; net loss $0.01/share.
- NGENLA global launch ongoing; earned $6.3M gross profit share from Pfizer in Q2 (up from $3.8M).
- Entered $250M note purchase agreement with HealthCare Royalty secured by NGENLA profit share; retains milestone upside.
- Board authorized $100M share repurchase program (~10.1% of shares outstanding).
- Sale of BioReference laboratory assets to Labcorp for $237.5M expected close end of Q3 2024.

## SEC filing metadata
- accession: 0001437749-24-025180
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000143774924025180/0001437749-24-025180-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000143774924025180/opk20240801_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-025180
- JSON: https://secwatch.observer/filing/0001437749-24-025180.json
- Plain text: https://secwatch.observer/filing/0001437749-24-025180.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.